rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BTAI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      US FDA approves at-home use of BioXcel's agitation drug
      Nov 16ReutersBTAITEVA
      Teva Pharmaceutical Industries Unit Buys Rights to BXCL501 From BioXcel Therapeutics
      Oct 27Yahoo FinanceBTAI
      Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
      Sep 12Yahoo FinanceBTAITEVA
      Biotech filed for bankruptcy 11 weeks before its big FDA decision
      Sep 8TheStreetBTAI
      Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

      Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

      Sep 4Yahoo FinanceBTAITEVA
      Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
      Sep 4BenzingaBTAIIMRN
      Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

      The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

      Aug 31Yahoo FinanceBTAITEVA
      Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

      TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.

      Aug 31Yahoo FinanceBTAITEVA
      BioXcel Therapeutics Initiates Chapter 11 and Sale Process

      Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

      Aug 29The Globe and MailBTAI
      Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75
      Aug 28BenzingaBTAINVT
      BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
      Aug 28BenzingaBTAITEVA
      Teva bids $57.5M for BioXcel’s agitation treatment asset
      Aug 28Investing.comBTAITEVA
      BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

      BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutic

      Aug 28Yahoo FinanceBTAITEVA
      BioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals

      BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA)

      Aug 28Yahoo FinanceBTAI
      Biopharma firm BioXcel Therapeutics files for bankruptcy in US
      Aug 28ReutersBTAI
      BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain

      Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

      Aug 26The Globe and MailBTAI

      This is the newest page. Registered accounts read further back.